Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study.
S A CampbellP E LightScot H SimpsonPublished in: Diabetic medicine : a journal of the British Diabetic Association (2019)
Costarting drug therapy with sitagliptin and metformin was associated with a lower likelihood of disease progression in people with type 2 diabetes compared with adding sitagliptin later.